Postoperative Complications Following Skull Base Tumor Resection
Launched by BEIJING TIANTAN HOSPITAL · Sep 5, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the complications that can occur after surgery to remove tumors located at the base of the skull. These tumors can be tricky to operate on because they are near important parts of the brain and nerves. The goal of the trial is to better understand how to manage patients during and after this type of surgery, as many people experience complications afterward.
To participate in this trial, you must be at least 18 years old and in generally good health (a physical status of I to III, meaning no serious health issues). You should be scheduled for elective surgery to remove a skull base tumor and be able to provide written consent. However, if you have serious heart, liver, or lung conditions, or if you have had certain heart problems recently, you may not be eligible. Participants in this trial can expect to be closely monitored during their surgery and recovery, and their experiences will help researchers improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and above
- • American Society of Anesthesiologists physical status I to III
- • Undergoing elective resection of skull base tumors
- • Obtaining written informed consent
- Exclusion Criteria:
- • Heart failure, myocarditis, pericarditis, and cardiomyopathy
- • Myocardial ischemia less than 6 months old
- • Severe arrhythmia
- • Severe bradycardia (heart rate below 50 beats per minute)
- • Unable to complete preoperative cardiac assessment
- • Severe liver dysfunction (Child Pugh C-grade)
- • Severe lung diseases
About Beijing Tiantan Hospital
Beijing Tiantan Hospital, affiliated with Capital Medical University, is a leading medical institution in China renowned for its expertise in neurology, neurosurgery, and various other specialties. As a prominent clinical trial sponsor, the hospital is committed to advancing medical research and improving patient outcomes through innovative studies. With a focus on high-quality clinical trials, Beijing Tiantan Hospital adheres to rigorous ethical standards and regulatory requirements, fostering collaboration with academic institutions and industry partners to facilitate the development of cutting-edge therapies and interventions. Its state-of-the-art facilities and experienced research team enable the hospital to play a pivotal role in the global medical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Yuming Peng
Study Chair
Beijing Tiantan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported